Janux Free Cash Flow Per Share vs Price To Sales Ratio Analysis

JANX Stock

USD 48.82 1.49 2.96%

Janux Therapeutics financial indicator trend analysis is infinitely more than just investigating Janux Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Janux Therapeutics is a good investment. Please check the relationship between Janux Therapeutics Free Cash Flow Per Share and its Price To Sales Ratio accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Janux Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Janux Stock please use our How to Invest in Janux Therapeutics guide.

Free Cash Flow Per Share vs Price To Sales Ratio

Free Cash Flow Per Share vs Price To Sales Ratio Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Janux Therapeutics Free Cash Flow Per Share account and Price To Sales Ratio. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Janux Therapeutics' Free Cash Flow Per Share and Price To Sales Ratio is 0.98. Overlapping area represents the amount of variation of Free Cash Flow Per Share that can explain the historical movement of Price To Sales Ratio in the same time period over historical financial statements of Janux Therapeutics, assuming nothing else is changed. The correlation between historical values of Janux Therapeutics' Free Cash Flow Per Share and Price To Sales Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow Per Share of Janux Therapeutics are associated (or correlated) with its Price To Sales Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Price To Sales Ratio has no effect on the direction of Free Cash Flow Per Share i.e., Janux Therapeutics' Free Cash Flow Per Share and Price To Sales Ratio go up and down completely randomly.

Correlation Coefficient

0.98

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Free Cash Flow Per Share

The amount of cash a company generates after accounting for capital expenditures, divided by the number of outstanding shares. It represents the cash available for dividends, share buybacks, or debt repayment per share.

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Janux Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Janux Therapeutics sales, a figure that is much harder to manipulate than other Janux Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Most indicators from Janux Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Janux Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Janux Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Janux Stock please use our How to Invest in Janux Therapeutics guide.At this time, Janux Therapeutics' Issuance Of Capital Stock is fairly stable compared to the past year. Enterprise Value is likely to rise to about 850.2 M in 2024, whereas Selling General Administrative is likely to drop slightly above 13.5 M in 2024.

	2021	2022	2023	2024 (projected)
Interest Expense	370K	4.0M	4.6M	4.9M
Depreciation And Amortization	113K	841K	2.0M	2.1M

Interest Expense Depreciation And Amortization

Janux Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Short Long Term Debt	Total Current Assets	Capital Stock	Net Working Capital	Short Term Debt
Total Assets		0.71	0.97	0.97	1.0	0.97	0.79	-0.63	-0.84	1.0	0.91	0.8	0.75	1.0	0.96	0.43	0.52	0.99	0.74	1.0	0.79	-0.48	1.0	1.0	1.0	-0.81
Short Long Term Debt Total	0.71		0.84	0.79	0.69	0.7	0.94	-0.11	-0.86	0.68	0.65	0.93	0.81	0.68	0.74	0.53	0.68	0.75	0.8	0.69	0.93	-0.53	0.68	0.74	0.68	-0.39
Other Current Liab	0.97	0.84		0.97	0.96	0.94	0.89	-0.53	-0.9	0.97	0.9	0.89	0.8	0.96	0.95	0.48	0.65	0.99	0.84	0.96	0.88	-0.51	0.96	0.98	0.96	-0.76
Total Current Liabilities	0.97	0.79	0.97		0.97	0.94	0.84	-0.62	-0.83	0.96	0.95	0.84	0.72	0.97	0.94	0.39	0.52	0.96	0.75	0.97	0.83	-0.44	0.97	0.97	0.96	-0.71
Total Stockholder Equity	1.0	0.69	0.96	0.97		0.97	0.77	-0.64	-0.83	1.0	0.9	0.78	0.73	1.0	0.96	0.42	0.48	0.99	0.7	1.0	0.77	-0.47	1.0	1.0	1.0	-0.79
Net Tangible Assets	0.97	0.7	0.94	0.94	0.97		0.84	-0.52	-0.9	0.97	0.87	0.85	0.84	0.97	1.0	0.61	0.5	0.97	0.72	0.97	0.84	-0.66	0.97	0.97	0.97	-0.8
Property Plant And Equipment Net	0.79	0.94	0.89	0.84	0.77	0.84		-0.18	-0.96	0.78	0.75	1.0	0.92	0.77	0.88	0.72	0.73	0.83	0.86	0.77	1.0	-0.74	0.77	0.81	0.77	-0.59
Net Debt	-0.63	-0.11	-0.53	-0.62	-0.64	-0.52	-0.18		0.16	-0.62	-0.78	-0.18	0.01	-0.65	-0.47	0.29	-0.22	-0.57	-0.38	-0.63	-0.15	-0.22	-0.65	-0.59	-0.65	0.66
Retained Earnings	-0.84	-0.86	-0.9	-0.83	-0.83	-0.9	-0.96	0.16		-0.84	-0.71	-0.97	-0.98	-0.82	-0.93	-0.8	-0.68	-0.88	-0.81	-0.83	-0.97	0.82	-0.83	-0.86	-0.83	0.67
Accounts Payable	1.0	0.68	0.97	0.96	1.0	0.97	0.78	-0.62	-0.84		0.9	0.79	0.75	1.0	0.96	0.45	0.52	0.99	0.73	1.0	0.78	-0.5	1.0	1.0	1.0	-0.82
Cash	0.91	0.65	0.9	0.95	0.9	0.87	0.75	-0.78	-0.71	0.9		0.75	0.57	0.91	0.87	0.27	0.57	0.89	0.77	0.9	0.72	-0.32	0.91	0.9	0.91	-0.79
Non Current Assets Total	0.8	0.93	0.89	0.84	0.78	0.85	1.0	-0.18	-0.97	0.79	0.75		0.93	0.78	0.89	0.73	0.73	0.84	0.86	0.78	1.0	-0.75	0.78	0.82	0.78	-0.6
Non Currrent Assets Other	0.75	0.81	0.8	0.72	0.73	0.84	0.92	0.01	-0.98	0.75	0.57	0.93		0.73	0.87	0.9	0.6	0.79	0.71	0.73	0.94	-0.9	0.73	0.77	0.73	-0.57
Cash And Short Term Investments	1.0	0.68	0.96	0.97	1.0	0.97	0.77	-0.65	-0.82	1.0	0.91	0.78	0.73		0.96	0.42	0.49	0.99	0.71	1.0	0.76	-0.47	1.0	1.0	1.0	-0.81
Common Stock Total Equity	0.96	0.74	0.95	0.94	0.96	1.0	0.88	-0.47	-0.93	0.96	0.87	0.89	0.87	0.96		0.65	0.55	0.97	0.75	0.96	0.88	-0.69	0.96	0.97	0.96	-0.79
Common Stock Shares Outstanding	0.43	0.53	0.48	0.39	0.42	0.61	0.72	0.29	-0.8	0.45	0.27	0.73	0.9	0.42	0.65		0.43	0.48	0.47	0.42	0.76	-1.0	0.42	0.45	0.42	-0.39
Non Current Liabilities Total	0.52	0.68	0.65	0.52	0.48	0.5	0.73	-0.22	-0.68	0.52	0.57	0.73	0.6	0.49	0.55	0.43		0.58	0.96	0.47	0.73	-0.43	0.5	0.53	0.5	-0.69
Other Stockholder Equity	0.99	0.75	0.99	0.96	0.99	0.97	0.83	-0.57	-0.88	0.99	0.89	0.84	0.79	0.99	0.97	0.48	0.58		0.78	0.99	0.82	-0.52	0.99	1.0	0.99	-0.81
Total Liab	0.74	0.8	0.84	0.75	0.7	0.72	0.86	-0.38	-0.81	0.73	0.77	0.86	0.71	0.71	0.75	0.47	0.96	0.78		0.7	0.85	-0.48	0.72	0.75	0.72	-0.78
Net Invested Capital	1.0	0.69	0.96	0.97	1.0	0.97	0.77	-0.63	-0.83	1.0	0.9	0.78	0.73	1.0	0.96	0.42	0.47	0.99	0.7		0.76	-0.47	1.0	1.0	1.0	-0.79
Property Plant And Equipment Gross	0.79	0.93	0.88	0.83	0.77	0.84	1.0	-0.15	-0.97	0.78	0.72	1.0	0.94	0.76	0.88	0.76	0.73	0.82	0.85	0.76		-0.77	0.77	0.81	0.76	-0.59
Short Long Term Debt	-0.48	-0.53	-0.51	-0.44	-0.47	-0.66	-0.74	-0.22	0.82	-0.5	-0.32	-0.75	-0.9	-0.47	-0.69	-1.0	-0.43	-0.52	-0.48	-0.47	-0.77		-0.47	-0.5	-0.48	0.44
Total Current Assets	1.0	0.68	0.96	0.97	1.0	0.97	0.77	-0.65	-0.83	1.0	0.91	0.78	0.73	1.0	0.96	0.42	0.5	0.99	0.72	1.0	0.77	-0.47		1.0	1.0	-0.81
Capital Stock	1.0	0.74	0.98	0.97	1.0	0.97	0.81	-0.59	-0.86	1.0	0.9	0.82	0.77	1.0	0.97	0.45	0.53	1.0	0.75	1.0	0.81	-0.5	1.0		1.0	-0.78
Net Working Capital	1.0	0.68	0.96	0.96	1.0	0.97	0.77	-0.65	-0.83	1.0	0.91	0.78	0.73	1.0	0.96	0.42	0.5	0.99	0.72	1.0	0.76	-0.48	1.0	1.0		-0.82
Short Term Debt	-0.81	-0.39	-0.76	-0.71	-0.79	-0.8	-0.59	0.66	0.67	-0.82	-0.79	-0.6	-0.57	-0.81	-0.79	-0.39	-0.69	-0.81	-0.78	-0.79	-0.59	0.44	-0.81	-0.78	-0.82

Click cells to compare fundamentals

Janux Therapeutics Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Janux Stock Analysis

When running Janux Therapeutics' price analysis, check to measure Janux Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Janux Therapeutics is operating at the current time. Most of Janux Therapeutics' value examination focuses on studying past and present price action to predict the probability of Janux Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Janux Therapeutics' price. Additionally, you may evaluate how the addition of Janux Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Janux Free Cash Flow Per Share vs Price To Sales Ratio Analysis

Free Cash Flow Per Share vs Price To Sales Ratio

Free Cash Flow Per Share vs Price To Sales Ratio Correlation Analysis

Correlation Coefficient

Free Cash Flow Per Share

Price To Sales Ratio

Janux Therapeutics fundamental ratios Correlations

Janux Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for Janux Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Accounts Payable	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Capital Stock	+ 1.0	Total Assets

Short Long Term Debt	- 1.0	Common Stock Shares Outstanding
Non Currrent Assets Other	- 0.98	Retained Earnings
Property Plant And Equipment Gross	- 0.97	Retained Earnings
Non Current Assets Total	- 0.97	Retained Earnings
Retained Earnings	- 0.96	Property Plant And Equipment Net
Common Stock Total Equity	- 0.93	Retained Earnings